This article was originally published in SRA
EU orphan drug legislation five years on
You may also be interested in...
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
New real-world data, presented at a recent diabetes conference in Madrid, showed that Abbott's FreeStyle Libre system provided several clinical benefits for patients with diabetes.